Sertoli-Leydig cell tumour, also known as arrhenoblastoma or androblastoma, is a member of the sex cord-stromal tumour group of ovarian and testicular cancers. The tumour is rare, comprising less than 1% of ovarian tumours,. While the tumour can occur at any age, it occurs most often in young adults.
A recent study has shown that CD56 can be a marker for tumors of this class.
Treatment consists of surgical resection alone with a unilateral salpingo-oophorectomy. The prognosis is generally good as the tumour tends to grow slowly and usually is benign: 25% are malignant.